Ionis Pharmaceuticals, Inc. (IONS) Current Ratio
- Current ratio · latest quarter: Value 7.89×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 7.89× | Current assets / current liabilities. $2.49B ÷ $315.64M ≈ 7.89× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 2.49B USD | Assets, Current |
| Current obligations | 315.64M USD | Liabilities, Current |
| Cash and equivalents | 350.06M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 1.14B USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory | 50.83M USD | Inventory, Net |
| Payables | 47.70M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.49B | $315.64M | $350.06M | $1.14B | (m) | $50.83M | $47.70M | (m) | 7.89× |
| 2026-03-31 | $2.94B | $716.59M | $173.38M | $1.12B | (m) | $5.56M | $26.03M | (m) | 4.10× |
| 2025-12-31 | $2.99B | $781.57M | $372.26M | $1.58B | (m) | $10.05M | $28.08M | (m) | 3.83× |
| 2025-09-30 | $2.52B | $903.46M | $338.34M | $1.28B | (m) | $10.47M | $14.33M | (m) | 2.79× |
| 2025-06-30 | $2.58B | $897.24M | $297.30M | $1.33B | (m) | $8.48M | $22.80M | (m) | 2.87× |
| 2025-03-31 | $2.42B | $250.29M | $264.19M | $1.23B | (m) | $11.50M | $17.46M | (m) | 9.66× |
| 2024-12-31 | $2.62B | $309.32M | $242.08M | $1.40B | (m) | $12.51M | $42.96M | (m) | 8.47× |
| 2024-09-30 | $2.71B | $304.57M | $334.61M | $1.49B | (m) | $28.45M | $9.05M | (m) | 8.91× |
| 2024-06-30 | $2.33B | $306.16M | $293.99M | $1.34B | (m) | $28.72M | $9.24M | (m) | 7.61× |
| 2024-03-31 | $2.42B | $327.65M | $348.89M | $1.30B | (m) | $30.26M | $13.08M | (m) | 7.37× |
| 2023-12-31 | $2.64B | $448.09M | $399.27M | $1.31B | (m) | $7.44M | $26.03M | (m) | 5.90× |
| 2023-09-30 | $2.58B | $404.21M | $352.06M | $1.34B | (m) | $25.63M | $5.62M | (m) | 6.39× |
| 2023-06-30 | $2.62B | $287.98M | $424.79M | $1.54B | (m) | $25.54M | $24.02M | (m) | 9.09× |
| 2023-03-31 | $2.54B | $259.22M | $309.03M | $1.47B | (m) | $22.20M | $10.50M | (m) | 9.81× |
| 2022-12-31 | $2.20B | $311.56M | $276.47M | $1.21B | (m) | $22.03M | $17.92M | (m) | 7.07× |
| 2022-09-30 | $2.15B | $283.45M | $314.99M | $1.12B | (m) | $20.64M | $20.55M | (m) | 7.59× |
| 2022-06-30 | $2.19B | $267.81M | $521.92M | $1.03B | (m) | $19.81M | $10.35M | (m) | 8.18× |
| 2022-03-31 | $2.25B | $228.45M | $542.51M | $1.51B | (m) | $24.03M | $16.13M | (m) | 9.86× |
| 2021-12-31 | $2.35B | $240.55M | $869.19M | $613.00M | (m) | $24.81M | $11.90M | (m) | 9.75× |
| 2021-09-30 | $2.16B | $279.78M | $632.95M | $1.35B | (m) | $22.93M | $8.36M | (m) | 7.71× |
| 2021-06-30 | $2.24B | $293.82M | $565.12M | $1.49B | (m) | $24.10M | $14.66M | (m) | 7.62× |
| 2021-03-31 | $1.99B | $295.11M | $414.15M | $1.41B | (m) | $22.20M | $9.51M | (m) | 6.74× |
| 2020-12-31 | $2.13B | $598.90M | $397.66M | $1.49B | (m) | $21.96M | $17.20M | (m) | 3.56× |
| 2020-09-30 | $2.54B | $244.57M | $633.06M | $1.70B | (m) | $22.17M | $16.22M | (m) | 10.37× |
| 2020-06-30 | $2.53B | $231.34M | $530.18M | $1.82B | (m) | $23.72M | $7.41M | (m) | 10.94× |
| 2020-03-31 | $2.56B | $258.02M | $486.19M | $1.90B | (m) | $22.89M | $21.17M | (m) | 9.91× |
| 2019-12-31 | $2.72B | $273.00M | $683.29M | $1.82B | (m) | $18.18M | $16.07M | (m) | 9.97× |
| 2019-09-30 | $2.41B | $231.78M | $247.94M | $1.97B | (m) | $19.38M | $13.15M | (m) | 10.39× |
| 2019-06-30 | $2.41B | $241.21M | $272.52M | $1.99B | (m) | $18.50M | $15.63M | (m) | 10.01× |
| 2019-03-31 | $2.37B | $252.47M | $375.81M | $1.88B | (m) | $11.06M | $13.33M | (m) | 9.40× |
| 2018-12-31 | $2.21B | $280.29M | $278.82M | $1.81B | (m) | $8.58M | $28.66M | (m) | 7.88× |
| 2018-09-30 | $2.08B | $260.24M | $479.89M | $1.48B | (m) | $8.38M | $13.58M | (m) | 7.99× |
| 2018-06-30 | $2.08B | $248.62M | $805.49M | $1.17B | (m) | (m) | $13.29M | (m) | 8.38× |
| 2018-03-31 | $1.14B | $212.64M | $227.50M | $807.80M | (m) | (m) | $13.83M | (m) | 5.38× |
| 2017-12-31 | $1.17B | $243.61M | $129.63M | $893.09M | (m) | $9.98M | $24.89M | (m) | 4.80× |
| 2017-09-30 | $1.11B | $177.65M | $159.18M | $851.62M | (m) | (m) | $23.52M | (m) | 6.25× |
| 2017-06-30 | $964.36M | $191.76M | $132.99M | $722.72M | (m) | (m) | $13.27M | (m) | 5.03× |
| 2017-03-31 | $962.37M | $170.58M | $114.22M | $746.06M | (m) | (m) | $23.24M | (m) | 5.64× |
| 2016-12-31 | $797.93M | $133.78M | $84.69M | $580.54M | (m) | (m) | $21.12M | (m) | 5.96× |
| 2016-09-30 | $730.33M | $106.89M | $84.28M | $603.57M | (m) | (m) | $15.68M | (m) | 6.83× |
| 2016-06-30 | $697.97M | $111.08M | $112.53M | $551.56M | (m) | (m) | $17.58M | (m) | 6.28× |
| 2016-03-31 | $763.91M | $124.50M | $93.34M | $610.47M | (m) | (m) | $19.46M | (m) | 6.14× |
| 2015-12-31 | $837.00M | $148.88M | $128.80M | $650.39M | (m) | (m) | $28.36M | (m) | 5.62× |
| 2015-09-30 | $868.26M | $122.20M | $126.59M | $685.60M | (m) | (m) | $19.29M | (m) | 7.11× |
| 2015-06-30 | $855.45M | $102.13M | $119.49M | $635.45M | (m) | (m) | $10.95M | (m) | 8.38× |
| 2015-03-31 | $835.43M | $100.29M | $148.35M | $546.71M | (m) | (m) | $16.49M | (m) | 8.33× |
| 2014-12-31 | $836.60M | $115.33M | $143.00M | $585.83M | (m) | (m) | $17.98M | (m) | 7.25× |
| 2014-09-30 | $681.16M | $107.33M | $73.22M | $518.77M | (m) | (m) | $15.63M | (m) | 6.35× |
| 2014-06-30 | $705.80M | $100.82M | $94.08M | $496.75M | (m) | (m) | $13.45M | (m) | 7.00× |
| 2014-03-31 | $722.05M | $100.84M | $161.78M | $469.51M | (m) | (m) | $9.87M | (m) | 7.16× |
| 2013-12-31 | $735.51M | $97.81M | $159.97M | $496.79M | (m) | (m) | $11.01M | (m) | 7.52× |
| 2013-09-30 | $763.30M | $103.28M | $256.41M | $414.49M | (m) | (m) | $8.78M | (m) | 7.39× |
| 2013-06-30 | $669.06M | $87.00M | $296.54M | $294.21M | (m) | (m) | $9.46M | (m) | 7.69× |
| 2013-03-31 | $431.83M | $70.30M | $107.65M | $264.26M | (m) | (m) | $5.38M | (m) | 6.14× |
| 2012-12-31 | $423.44M | $74.32M | $124.48M | $249.96M | (m) | (m) | $10.24M | (m) | 5.70× |
| 2012-09-30 | $361.59M | $51.60M | $84.56M | $259.01M | (m) | (m) | $5.26M | (m) | 7.01× |
| 2012-06-30 | $350.42M | $55.06M | $85.64M | $250.38M | (m) | (m) | $6.19M | (m) | 6.36× |
| 2012-03-31 | $347.61M | $61.71M | $56.39M | $277.55M | (m) | (m) | $5.34M | (m) | 5.63× |
| 2011-12-31 | $360.14M | $76.11M | $65.48M | $278.19M | (m) | (m) | $8.30M | (m) | 4.73× |
| 2011-09-30 | $377.09M | $83.54M | $55.26M | $309.50M | (m) | (m) | $6.65M | (m) | 4.51× |
| 2011-06-30 | $410.72M | $91.98M | $85.02M | $310.16M | (m) | (m) | $3.07M | (m) | 4.47× |
| 2011-03-31 | $437.39M | $94.40M | $86.20M | $340.62M | (m) | (m) | $4.65M | (m) | 4.63× |
| 2010-12-31 | $483.14M | $105.89M | $70.05M | $402.30M | (m) | (m) | $6.52M | (m) | 4.56× |
| 2010-09-30 | $507.55M | $100.92M | $100.12M | $397.78M | (m) | (m) | $3.39M | (m) | 5.03× |
| 2010-06-30 | $536.88M | $105.21M | $46.04M | $475.99M | (m) | (m) | $5.36M | (m) | 5.10× |
| 2009-12-31 | $596.13M | $111.44M | $105.25M | $469.06M | (m) | (m) | $4.70M | (m) | 5.35× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |